

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 451/04, A61K 31/445, C07D 453/02, 211/90, 405/12, 409/12		A1	(11) International Publication Number: WO 97/30048
			(43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/IB97/00058			(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 27 January 1997 (27.01.97)			
(30) Priority Data: PCT/IB96/00132 19 February 1996 (19.02.96) WO			
(34) Countries for which the regional or international application was filed: CA et al.			
(71) Applicant (for JP only): PFIZER PHARMACEUTICALS INC. [JP/JP]; Mitsui Building, 1-1, Nishi-shinjuku 2-chome, Shinjuku-ku, Tokyo 163 (JP).			
(71) Applicant (for all designated States except JP US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			Published With international search report.
(72) Inventor; and			
(75) Inventor/Applicant (for US only): IKEDA, Takafumi [JP/JP]; 151-7, Miyaji-cho, Handa-shi, Aichi-ken 475 (JP).			
(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).			

(54) Title: **1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS**

(57) Abstract

A compound of formula (I), and its pharmaceutically acceptable salts, wherein A¹ and A² are each halo; X is CO, S(O)₂ or S(O)-(CH₂)_n wherein S atom is directly attached to the phenyl and n is 0, 1 or 2; and R¹ is 8-azabicyclo[3.2.1]octyl, quinuclidinyl, bicyclo[3.3.0]octyl, C₃₋₁₀ cycloalkyl, 2,3,5,6-tetrahydro-4H-thiopyranyl or C₃₋₆ cycloalkyl-C₁₋₄ alkyl, optionally substituted with C₁₋₄ alkyl, hydroxy, dioxaranyl or oxo. The novel dihydropyridine compounds of this invention have excellent bradykinin antagonistic activity and are thus useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma or the like in mammalian, especially humans.



(I)